Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes
Chih-Lang Lin, Kuan-Chou Lin, Jung-Min Yu, Chia-Lun Chang, Yu-Yi Lin, Chih-Yuan Fang, Wan-Ming Chen, Szu-Yuan Wu · 2026
Read Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes by Chih-Lang Lin, Kuan-Chou Lin, Jung-Min Yu, Chia-Lun Chang, Yu-Yi Lin, Chih-Yuan Fang, Wan-Ming Chen, Szu-Yuan Wu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13601590.txt.
Description
People who have both atrial fibrillation and type 2 diabetes face a high stroke risk even with standard care. Chih-Lang Lin and co-authors compare the newer drug tirzepatide against older GLP-1 receptor agonists, a class of diabetes drugs, using records from a large international health network. They ask whether starting tirzepatide links to fewer strokes.
In 14,118 matched pairs of patients, tirzepatide use went with lower risks of any stroke, bleeding stroke, and death from any cause. The gap in stroke risk was 2.1 percentage points at one year, and the death gap was 6.2 points. Because the study is observational, the authors stress that randomized trials are needed before treatment advice can change.
Catalog record
| CREATOR | Chih-Lang Lin, Kuan-Chou Lin, Jung-Min Yu, Chia-Lun Chang, Yu-Yi Lin, Chih-Yuan Fang, Wan-Ming Chen, Szu-Yuan Wu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 56 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |